Search research articles
Contact Us
Filters
Showing results (271-280 of 284) with videos related to
Page
of 29
Sort By:
BMC Cancer
|
October 4, 2025
Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers
Ying Liu, Wei He, Qi Wu, et al.
The New England Journal of Medicine
|
June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Patrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
The New England Journal of Medicine
|
April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2025
Neoadjuvant Osimertinib for Resectable <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer
Jianxing He, Masahiro Tsuboi, Walter Weder, et al.
The Lancet. Oncology
|
November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Future Oncology (London, England)
|
February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Jian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Annals of Translational Medicine
|
September 16, 2022
Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501)
You-Sheng Mao, Shu-Geng Gao, Yin Li, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 284) with videos related to
Sort By:
Page
of 29
BMC Cancer
|
October 4, 2025
Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers
Ying Liu, Wei He, Qi Wu, et al.
The New England Journal of Medicine
|
June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Patrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
The New England Journal of Medicine
|
April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2025
Neoadjuvant Osimertinib for Resectable <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer
Jianxing He, Masahiro Tsuboi, Walter Weder, et al.
The Lancet. Oncology
|
November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Future Oncology (London, England)
|
February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 7, 2018
The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)
Song-Tao Xu, Jun-Jie Xi, Wen-Zhao Zhong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 13, 2020
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Jian Zeng, Wei-Min Mao, Qi-Xun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.
Annals of Translational Medicine
|
September 16, 2022
Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501)
You-Sheng Mao, Shu-Geng Gao, Yin Li, et al.
Page
of 29